Literature DB >> 21628667

Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy.

Tae-Wook Chun1, Danielle Murray, J Shawn Justement, Claire W Hallahan, Susan Moir, Colin Kovacs, Anthony S Fauci.   

Abstract

Residual plasma viremia (<50 copies/mL) persists in certain human immunodeficiency virus (HIV)-infected individuals receiving antiretroviral therapy (ART); however, the relationship between the degree of residual plasma viremia, the size of HIV reservoirs, and the level of immune activation has not been delineated. Here, we demonstrate that residual plasma viremia correlates with the size of the CD4(+) T cell viral reservoir, but not with markers of immune activation, suggesting that reactivation of the latent viral reservoir may not be the sole source of residual plasma viremia. Novel therapeutic strategies aimed at targeting the source of residual viremia may be necessary to achieve viral eradication.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21628667      PMCID: PMC3105034          DOI: 10.1093/infdis/jir208

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.

Authors:  Tae-Wook Chun; David C Nickle; J Shawn Justement; Danielle Large; Alice Semerjian; Marcel E Curlin; M Angeline O'Shea; Claire W Hallahan; Marybeth Daucher; Douglas J Ward; Susan Moir; James I Mullins; Colin Kovacs; Anthony S Fauci
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

2.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

3.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

4.  Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Sara Gianella; Elizabeth Sinclair; Lorrie Epling; Qingsheng Li; Lijie Duan; Alex L M Choi; Valerie Girling; Terence Ho; Peilin Li; Katsuya Fujimoto; Harry Lampiris; C Bradley Hare; Mark Pandori; Ashley T Haase; Huldrych F Günthard; Marek Fischer; Amandeep K Shergill; Kenneth McQuaid; Diane V Havlir; Joseph K Wong
Journal:  J Infect Dis       Date:  2010-10-12       Impact factor: 5.226

5.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Amandeep K Shergill; Kenneth McQuaid; Sara Gianella; Harry Lampiris; C Bradley Hare; Mark Pandori; Elizabeth Sinclair; Huldrych F Günthard; Marek Fischer; Joseph K Wong; Diane V Havlir
Journal:  AIDS       Date:  2010-10-23       Impact factor: 4.177

6.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

7.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.

Authors:  J B Dinoso; S Y Kim; A M Wiegand; S E Palmer; S J Gange; L Cranmer; A O'Shea; M Callender; A Spivak; T Brennan; M F Kearney; M A Proschan; J M Mican; C A Rehm; J M Coffin; J W Mellors; R F Siliciano; F Maldarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

8.  New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.

Authors:  Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

9.  Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy.

Authors:  Tae-Wook Chun; David C Nickle; Jesse S Justement; Jennifer H Meyers; Gregg Roby; Claire W Hallahan; Shyam Kottilil; Susan Moir; Joann M Mican; James I Mullins; Douglas J Ward; Joseph A Kovacs; Peter J Mannon; Anthony S Fauci
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

10.  The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.

Authors:  Rajesh T Gandhi; Lu Zheng; Ronald J Bosch; Ellen S Chan; David M Margolis; Sarah Read; Beatrice Kallungal; Sarah Palmer; Kathy Medvik; Michael M Lederman; Nadia Alatrakchi; Jeffrey M Jacobson; Ann Wiegand; Mary Kearney; John M Coffin; John W Mellors; Joseph J Eron
Journal:  PLoS Med       Date:  2010-08-10       Impact factor: 11.069

View more
  77 in total

Review 1.  HIV reservoirs and strategies for eradication.

Authors:  Miranda Z Smith; Fiona Wightman; Sharon R Lewin
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

2.  Paucity of HIV DNA methylation in latently infected, resting CD4+ T cells from infected individuals receiving antiretroviral therapy.

Authors:  Jana Blazkova; Danielle Murray; J Shawn Justement; Emily K Funk; Amy K Nelson; Susan Moir; Tae-Wook Chun; Anthony S Fauci
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

3.  HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability.

Authors:  Jean Ruelle; Laurent Debaisieux; Ellen Vancutsem; Annelies De Bel; Marie-Luce Delforge; Denis Piérard; Patrick Goubau
Journal:  BMC Infect Dis       Date:  2012-04-24       Impact factor: 3.090

4.  Epigenetic regulation of HIV-1 latency in astrocytes.

Authors:  Srinivas D Narasipura; Stephanie Kim; Lena Al-Harthi
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

5.  HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment.

Authors:  Katherine Luzuriaga; Barbara Tabak; Manuel Garber; Ya Hui Chen; Carrie Ziemniak; Margaret M McManus; Danielle Murray; Matthew C Strain; Douglas D Richman; Tae-Wook Chun; Coleen K Cunningham; Deborah Persaud
Journal:  J Infect Dis       Date:  2014-05-21       Impact factor: 5.226

6.  Delayed HIV detection among infants exposed to postnatal antiretroviral prophylaxis during breastfeeding.

Authors:  Caroline C King; Athena P Kourtis; Deborah Persaud; Julie A E Nelson; Carrie Ziemniak; Michael G Hudgens; Gerald Tegha; Charles S Chasela; Denise J Jamieson; Charles M van der Horst
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

Review 7.  Attacking the HIV reservoir from the immune and viral perspective.

Authors:  Marta Massanella; Javier Martinez-Picado; Julià Blanco
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

8.  Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.

Authors:  David Palesch; Steven E Bosinger; Maud Mavigner; James M Billingsley; Cameron Mattingly; Diane G Carnathan; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Guido Silvestri
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 9.  Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Luis Barcena; Randall Tressler
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

10.  Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.

Authors:  Silvia Baroncelli; Maria Franca Pirillo; Clementina Maria Galluzzo; Anna Degli Antoni; Nicoletta Ladisa; Daniela Francisci; Gabriella d'Ettorre; Daniela Segala; Angela Vivarelli; Federica Sozio; Oscar Cirioni; Liliana Elena Weimer; Vincenzo Fragola; Giustino Parruti; Marco Floridia
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.